Literature DB >> 17549444

[Local intravenous fibrinolysis in deep cerebral vein thrombosis].

R Huber1, H-J Gdynia, P Kühnlein, B Schmitz.   

Abstract

Acute cerebral vein and dural sinus thrombosis are usually treated with unfractionated intravenous heparin. Progression of symptoms after appropriate heparin dosage appears to be a rare event. In the literature only single case reports or small case series dealing with local intravenous fibrinolysis are available. Here we describe a 44-year-old woman with progressive thrombosis of the sinus rectus and right sinus transversus upon an appropriate dosage of heparin who was successfully treated with urokinase 12 h after symptom onset. This case demonstrates that local thrombolysis should be discussed in patients with progression of the clinical or radiological picture under sufficient heparin therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549444     DOI: 10.1007/s00115-007-2299-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  11 in total

Review 1.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

2.  Causes and predictors of death in cerebral venous thrombosis.

Authors:  Patrícia Canhão; José M Ferro; Arne G Lindgren; Marie-Germaine Bousser; Jan Stam; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2005-07-07       Impact factor: 7.914

3.  Heparin treatment in sinus venous thrombosis.

Authors:  K M Einhäupl; A Villringer; W Meister; S Mehraein; C Garner; M Pellkofer; R L Haberl; H W Pfister; P Schmiedek
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

4.  Long-term prognosis of cerebral vein and dural sinus thrombosis. results of the VENOPORT study.

Authors:  J M Ferro; M G Lopes; M J Rosas; M A Ferro; J Fontes
Journal:  Cerebrovasc Dis       Date:  2002       Impact factor: 2.762

5.  Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis.

Authors:  Simone Appenzeller; Carlos Borelli Zeller; Joyce M Annichino-Bizzachi; Lilian T L Costallat; Leonardo Deus-Silva; Barbara Voetsch; Andreia V Faria; Verônica A Zanardi; Benito P Damasceno; Fernando Cendes
Journal:  Clin Neurol Neurosurg       Date:  2004-11-18       Impact factor: 1.876

6.  Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis.

Authors:  M Wasay; R Bakshi; S Kojan; G Bobustuc; N Dubey; D H Unwin
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

7.  Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin.

Authors:  J L Frey; G J Muro; C G McDougall; B L Dean; H K Jahnke
Journal:  Stroke       Date:  1999-03       Impact factor: 7.914

8.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

9.  MR staging of acute dural sinus thrombosis: correlation with venous pressure measurements and implications for treatment and prognosis.

Authors:  F Y Tsai; A M Wang; V B Matovich; M Lavin; B Berberian; T M Simonson; W T Yuh
Journal:  AJNR Am J Neuroradiol       Date:  1995-05       Impact factor: 3.825

Review 10.  Thrombolysis for cerebral vein and dural sinus thrombosis.

Authors:  A Ciccone; P Canhão; F Falcão; J M Ferro; R Sterzi
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.